CBD Market 'Surges' As FDA Delays Setting Regulatory Policy – NPA

FDA should formalize its internal policy on CBD enforcement or create a pathway to make it compliant for use in supplements, says NPA President Daniel Fabricant. NPA and PCPC submitted comments on FDA request for input on agency's action at ongoing United Nations meeting on drug policy.

Cannibis

FDA's delay in implementing an enforcement strategy for using cannabidiol in dietary supplements and food as the market for the products is “surging” and states continue to legalize cannabis is “troubling,” says the Natural Products Association.

FDA should either formalize it internal policy on CBD enforcement in a “meaningful” way or create a pathway removing the...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation